Director Laura Tadvalkar resigns from Hemab Therapeutics board effective May 8, 2026

Hemab Therapeutics Holdings, Inc.

Laura Tadvalkar, Ph.D., resigned as a member of the Board, effective May 8, 2026.
Resignation not related to any disagreement with the Company on operations, policies or practices.
No replacement director announced; Board size reduced by one.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Laura Tadvalkar

Director

COAG · Hemab Therapeutics Holdings, Inc.

Effective: 2026-05-08
Filed: May 11, 2026, 4:01 PM ET

On May 8, 2026, Laura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Laura Tadvalkar resigned as Director at Hemab Therapeutics Holdings, Inc..

Action: resigned
Role: Director

Exact text from the filing

On May 8, 2026, Laura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.

View on SEC.gov

Hemab Therapeutics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-216699

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.